ATLCAR.k.CD28 cells (UNC Lineberger Comprehensive Cancer Center)

N/A

Report date: 2023/05/05 18:01:54

Base Information

Drug NameATLCAR.k.CD28 cells (UNC Lineberger Comprehensive Cancer Center)
Drug Alias NameT Lymphocytes Expressing the Kappa Chimeric Antigen Receptor (CAR) and CD28 Endodomain
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-CD28
TargetsT-cell-specific surface glycoprotein CD28
Therapy Area/IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesUnc Lineberger Comprehensive Cancer Center
China Registration ClassN/A

Develop Information

Active CompaniesUnc Lineberger Comprehensive Cancer Center
Inactive CompaniesN/A
Active IndicationsLymphoma, Mantle-CellLymphoma, FollicularLymphoma, B-Cell, Marginal Zone +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A